Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;60(6):957-63.
doi: 10.1002/pbc.24420. Epub 2012 Dec 19.

Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia

Stephen P Hunger  1 , Mignon L Loh, James A Whitlock, Naomi J Winick, William L Carroll, Meenakshi Devidas, Elizabeth A Raetz; COG Acute Lymphoblastic Leukemia Committee
Affiliations
Review

Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia

Stephen P Hunger et al. Pediatr Blood Cancer. 2013 Jun.

Abstract

Approximately 90% of the 2,000 children, adolescents, and young adults enrolled each year in Children's Oncology Group acute lymphoblastic leukemia (ALL) trials will be cured. However, high-risk subsets with significantly inferior survival remain, including infants, newly diagnosed patients with age ≥10 years, white blood count ≥50,000/µl, poor early response or T-cell ALL, and relapsed ALL patients. Effective strategies to improve survival include better risk stratification, optimizing standard chemotherapy and combining targeted therapies with cytotoxic chemotherapy, the latter of which is dependent upon identification of key driver mutations present in ALL.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Mignon Loh is a member of the DSMC for a Bristol Myers Squibb sponsored trail of dasatinib in Ph+ leukemias. Stephen Hunger owns stock in Amgen, which markets blinatumomab.

References

    1. Ries LAG, Smith MA, Gurney JG, et al., editors. National Cancer Institute, SEER Program. Bethesda, MD: 1999. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. NIH Pub. No. 99-4649.
    1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–2634. - PMC - PubMed
    1. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18–24. - PubMed
    1. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG) Blood. 2007;109:926–935. - PMC - PubMed
    1. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children’s Oncology Group study. Blood. 2008;111:5477–5485. - PMC - PubMed

Publication types

MeSH terms

Substances